UFP Technologies Inc. (UFPT) - 10-K Summary
Business Context and Reporting Period
Company: UFP Technologies, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: UFP is a contract development and manufacturing organization specializing in single-use and single-patient medical devices. The company serves as a vital link in the medical device supply chain, providing custom-engineered solutions for minimally invasive surgery, infection prevention, wound care, and orthopedics. The company operates as a single reportable segment.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Net Sales | $602.8 million | $504.4 million | +19.5% |
| Gross Profit | $170.4 million | $146.7 million | +16.2% |
| Gross Margin | 28.3% | 29.1% | -0.8 pts |
| Operating Income | $92.3 million | $80.9 million | +14.1% |
| Net Income | $68.3 million | $59.0 million | +15.8% |
| Diluted EPS | $8.75 | $7.58 | +15.4% |
| Operating Cash Flow | $91.9 million | $66.6 million | +38.0% |
| Total Debt (Outstanding) | $135.5 million | $189.4 million | -28.5% |
| Cash & Equivalents | $20.3 million | $13.5 million | +50.4% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 19.5% primarily driven by a 23.2% growth in the medical market. Acquisitions completed in 2024 and 2025 contributed approximately $168.3 million in sales in 2025, compared to $73.1 million in 2024. Organic sales growth was 1.5%.
- Margin Compression: Gross margin decreased to 28.3% from 29.1%. Management attributes this to a 3.8% increase in overhead and labor costs, partially offset by a 3.0% decrease in material costs. A specific "AJR Labor Issue" (workforce turnover due to E-Verify protocols) added over $6.3 million in incremental labor costs. Absent this issue, gross margin would have been 29.3%.
- SG&A Expenses: Selling, General, and Administrative expenses rose 24.5% to $77.4 million, largely due to increased headcount and back-office resources required for recent acquisitions.
- Debt Reduction: Total long-term debt decreased significantly as the company paid down the revolving line of credit and made principal payments on the term loan.
Guidance, Outlook, Risks, and Unusual Items
- Cyber Incident (Unusual Item): On February 14, 2026, the company detected a material IT systems incident ("Cyber Incident"). While the company believes systems are restored and the incident is not reasonably likely to materially impact financial condition, it is investigating potential data exfiltration. Costs are expected to be partially reimbursed by insurance.
- Customer Concentration: The company relies heavily on two customers: Intuitive Surgical SARL (24.3% of 2025 sales) and Stryker Corporation (21.5% of 2025 sales). Together, they represent nearly half of total revenue.
- Acquisition Strategy: The company continues to pursue strategic acquisitions to expand capacity and capabilities, having closed four deals in 2025 (TPI, UNIPEC, AJR Specialty, AJR Custom Foam).
- Tariffs: The company notes a dynamic tariff environment but estimates that unreimbursed tariffs were immaterial to 2025 results.
- Outlook: Management believes existing resources and cash flow will be sufficient to fund operations and capital requirements for the next twelve months. No specific numerical guidance for 2026 was provided in this text.
Investor Verification Checklist
- Cyber Incident Impact: Verify the final cost of the February 2026 Cyber Incident, the extent of any data breach, and potential regulatory fines or litigation risks.
- Customer Dependency: Monitor the stability of contracts with Intuitive Surgical and Stryker, which collectively account for ~46% of revenue.
- Acquisition Integration: Assess the integration progress of 2024 and 2025 acquisitions and whether they are delivering expected synergies and margin improvements.
- Labor Costs: Track the resolution of the "AJR Labor Issue" and its ongoing impact on labor efficiency and gross margins.
- Debt Covenants: Confirm continued compliance with the Third Amended and Restated Credit Agreement covenants (fixed-charge coverage and debt-to-EBITDA ratios).